Lanreotide Acetate cas 127984-74-1
Lanretide acetate is the acetate of lanretide, lanretide is somatostatin analogue and similar to octreotide. For the treatment of acromegaly and symptomatic neuroendocrine tumors.
Acromegaly is a rare disease caused by the excessive secretion of growth hormone (GH) by somatohormone type pituitary adenoma. Patients usually have structural changes and endocrine and metabolic disorders due to excessive GH and insulin-like growth factor (IGF-1), and their quality of life and longevity are seriously affected. Long-acting somatostatin analogues (SSA) represented by Lanretide acetate can effectively inhibit GH secretion, reduce tumor volume, and significantly improve patients' quality of life, which is the first choice of drug therapy. On December 18, 2019, Lanretide acetate sustained release injection (pre-filled) was officially approved by the National Drug Administration Chemicalbook (NMPA) for use when growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels in the blood are still abnormal after surgery and/or radiation therapy. Or the treatment of acromegaly without surgery and/or radiation therapy, opening a new era of treatment. It brings a new choice for the drug treatment of acromegaly with innovative formulation technology, rich evidence of efficacy, and extraordinary use experience. In fact, Lanretide acetate sustained-release injection (pre-filled) has been registered in about 70 countries around the world and is one of the long-acting Ssas recommended by multiple guidelines and consensus at home and abroad.
Properties of Lanretide acetate
1.1 Melting point >165°C (dec.)
1.2 Storage conditions -20°C
1.3 solubility DMSO (Slightly),
1.4 Methanol (Slightly)
1.5 form powder
1.6 color white to off-white
1.7 CAS number 127984-74-1
1.8 Molecular formula C54H69N11O10S2
Commonly known as Lanreotide acetate in English
CAS number 127904-74-1 Molecular weight 1156.375
Density N/A Boiling point N/A
Molecular formula C56H73N11O12S2 Melting point N/A